150
Participants
Start Date
May 20, 2022
Primary Completion Date
July 1, 2026
Study Completion Date
July 31, 2026
WTX-124
Investigation Product Monotherapy
pembrolizumab
Investigation Product in combination with approved therapy
TERMINATED
Westchester Medical Center, Hawthorne
RECRUITING
Roswell Park Comprehensive Cancer Care, Buffalo
RECRUITING
Emory Winship Cancer Institute, Atlanta
RECRUITING
Moffitt Cancer Center, Tampa
RECRUITING
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
RECRUITING
Minnesota Oncology Hematology, P.A., Maple Grove
RECRUITING
Northwestern University, Chicago
RECRUITING
NEXT Oncology, Houston
RECRUITING
NEXT Oncology, San Antonio
RECRUITING
HonorHealth, Scottsdale
RECRUITING
Providence Cancer Institute Franz Clinic, Portland
RECRUITING
Hackensack University Medical Center, Hackensack
RECRUITING
Texas Oncology - Austin Midtown, Austin
RECRUITING
University of Texas Southwestern Medical Center, Dallas
Merck Sharp & Dohme LLC
INDUSTRY
Werewolf Therapeutics, Inc.
INDUSTRY